Published in Hematology Week, January 12th, 2009
"The effectiveness of anticoagulants, antioxidants, anti-inflammatory drugs, and vasodilatory drugs in improving flap survival has been studied. Nebivolol isa new-generation selective beta(1)-adrenoreceptor blocking agent that has vasodilatory, antithrombotic, antioxidative, and anti-inflammatory effects. The aim of this experimental study was to investigate the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.